AbbVie’s neuroscience portfolio now contributes over 17% of the company’s total revenues, driven by robust demand for Botox, Vraylar and its migraine therapy. During the third quarter, neuroscience sales grew by 22% year-over-year, outpacing the company’s overall growth rate. Botox units increased 15% as international launches in Brazil and Japan gained traction, while Vraylar prescriptions rose 28%, reflecting expanded label approvals for bipolar depression. The migraine treatment posted 35% growth through new formulary placements in major U.S. managed-care plans and targeted patient-support programs.

Generali Asset Management SPA SGR reduced its position by 7.3%, selling 6,172 shares to hold 78,122 shares valued at $18.1 million as of the third quarter filing. In contrast, Banque Pictet & Cie SA boosted its stake by 89.2%, adding 157,480 shares to reach 333,971 shares worth $77.3 million. Meanwhile, Vanguard Group increased its holdings by 1.9%, ending the period with 177.3 million shares, and Norges Bank initiated a new position of approximately $4.29 billion. Institutional ownership remains high at roughly 70% of outstanding shares, underscoring continued confidence from large asset managers.

Analysts maintain a constructive view on AbbVie’s near-term outlook, with three firms assigning Strong Buy ratings and thirteen assigning Buy. The consensus price target sits near $246, suggesting 8% upside from current levels. Commentators highlight mid-teens EPS growth in 2025 driven by Skyrizi and Rinvoq in immunology, while pipeline assets in oncology and virology undergo mid-stage studies. The quarterly dividend was increased to $1.73 per share, translating into a 3.0% yield and a payout ratio below 100%, supported by free cash flow that exceeded $14 billion over the trailing twelve months. Potential risks include gradual Humira revenue decline and leverage of $60 billion, but the clean loss-of-exclusivity profile and strong cash generation underpin the buy-and-hold thesis.